MoST is a two part research program with the aim of treating as many patients as possible with personalised therapies.
These personalised therapies also link with clinical trials which are conducted in a series of steps which investigate the safety and efficacy of new cancer treatments and new drug combinations. The ultimate aim is to discover what the best standard treatment is, and whether a new treatment is better than existing ones.
Trials do not always focus on drugs, radiotherapy and surgical approaches, but as a rare cancer patient these are probably the ones you will be most likely to participate in.
In Phase 1, researchers use a tissue or blood sample to identify any known DNA or protein markers in the cancer that may be able to guide treatment.
If a molecular feature is identified in Phase 1 then targeted treatment may be available to the patient as part of a MoST study or a partnered program. Treatment sites are located around Australia.
Who is this for?
If you are over 18 and have been diagnosed with an advanced or metastatic cancer and have limited standard treatment options.
Information for doctors
1. Molecular Screening.
Molecular screening is performed using a 170 gene panel and other molecular assays. The primary objective is to identify clinically actionable biomarkers in tumour tissue to be used to guide treatment. Following screening the Molecular Tumour Board (MTB) report will be sent to you to discuss with the patient.
2. Multiple clinical sub-studies evaluating the activity of novel targeted treatments.
If the patient is recommended a MosT clinical sub-study you may refer them to commence treatment. Please note, sub-study slots are in high demand and availability may vary.
For information on referrals, contact:
Rare Cancers AustraliaGarvan Institute
Still have questions?
We have a friendly team available to chat about any questions you may have, or just to lend an ear if you’re having a tough time.
Call 1800 257 600Have us call you